Brise Pharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biopharma company creating small molecule immunomodulators for cancer and autoimmune disorders.
OncologyImmunology
Technology Platform
A small molecule discovery platform focused on immunomodulation, targeting intracellular immune checkpoints and inflammatory signaling pathways with oral agents.
Opportunities
Significant market need for oral, cost-effective immunotherapies that can be used in combination regimens or where biologics are unsuitable.
Risk Factors
High risk of clinical failure if small molecule efficacy cannot rival monoclonal antibodies, and crowded competitive landscape.
Competitive Landscape
Enters a field dominated by biologic drugs, requiring clear demonstration of comparable efficacy and the convenience benefits of an oral therapy.